Eyecare

Byooviz, the first FDA approved ophthalmology biosimilar for macular degeneration, will be priced 40% lower than the reference product. It will be commercially available on July 1, 2022.

If approved, Orasis’ low-dose pilocarpine would be the second product that improves presbyopia, which is the age-related loss of clear up-close vision. The company plans to submit an NDA in the second half of the year.

Phase 3 trials show CSF-1, a low-dose pilocarpine, met clinical endpoints for improving presbyopia, or age-related blurry vision.

Xipere is a targeted treatment that is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.

Cystaran is a topical ophthalmic therapy that is used to treat a rare genetic disorder.

This expands commercial coverage to 118 million lives and Medicare coverage to 7.1 million lives.

The use of digital devices has surged significantly as people spend more time at home, with Americans logging an average of 13 hours per day watching screens. That compares to between seven and 10 hours per day before the COVID-19 pandemic started, with the increase in screen time likely contributing to more exposure to blue light.

Vuity, developed by Allergan, is a once-daily eye drop to treat presbyopia.

Xipere is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.

Genentech’s Susvimo is a refillable implant that delivers medication continuously for up to six months.

Tyrvaya is a twice daily nasal spray, a first for the treatment of dry eye disease.

Biogen/Samsung Bioepis’ Byooviz is a biosimilar of Genentech’s Lucentis.

The American Academy of Ophthalmology says biosimilar alternatives to Avastin have never been tested in the eye.

Diana Do, MD, and Steven Peskin, MD, MBA, FACP, discuss unmet needs and future approaches to treatment in wet AMD.

Steven Peskin, MD, MBA, FACP, provides insight into managed care considerations of wet AMD including clinical evidence evaluation, formulary management, and value-based agreements.

Diana Do, MD, discusses outcomes of interest for anti-VEGF agents, clinical evidence supporting the treat-and-extend approach, and strategies to overcome financial barriers in wet AMD.

Diana Do, MD, provides insight into anti-VEGF treatment selection for individual patients, evaluation of patient response to therapy, and considerations for switching of agents.

Diana Do, MD, provides an overview of available anti-VEGF agents used in the treatment of wet AMD and Steven Peskin, MD, MBA, FACP, discusses management strategies employed with these agents.

Diana Do, MD, and Steven Peskin, MD, MBA, FACP, discuss overtreatment and undertreatment in wet AMD in addition to the risks associated with delays in therapy.

Steven Peskin, MD, MBA, FACP, discusses drivers of cost and goals of therapy in wet AMD, and Diana Do, MD, discusses the different treatment approaches to the disease.

Glaucoma affects many people across the globe, but primarily, it's affecting African Americans due to access.

Three commercial plans now cover the corticosteroid Eysuvis.

Young adults, in particular, are more likely to seek out and place high value on telemedicine for eye care and those in vulnerable populations are benefitting most, according to an annual vision wellness study by VersantHealth.

Optometrists say their wide distribution and medical expertise make them ideal candidates to administer the COVID-19 vaccine. As healthcare workers they also want to be prioritized to receive the vaccine.

The study investigates the various eye symptoms indicative of conjunctivitis in relation to COVID-19.

Researchers say their study is the first to look at race as a factor in how people with diabetic macular edema respond to treatment with Avastin.

Falls are the current leading cause of injuries for older Americans, and many of them result in permanent disability and fatalities. The risk of falling for older adults doubles if they have impaired vision from a degenerative eye disease like diabetic retinopathy.

Rather than stopping hydroxychloroquine altogether, doses could be reduced and patients monitored if there are signs of retinopathy, say the authors of a commentary in the American Journal of Ophthalmology.

Study shows 12% retained sight for driving and 15% for reading.